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Introduction {#sec1}
============

In the adult, hematopoiesis is sustained by hematopoietic stem cells (HSCs) that have the ability to self-renew and to generate all blood lineages. In contrast, during embryogenesis, hematopoiesis is established in successive waves that result in the production of different types of blood lineages ([@bib7], [@bib30]). The first HSCs emerge intra-embryonically ([@bib9], [@bib12]) in the region where the aorta, gonads, and mesonephros (AGM) are localized in the mid-gestation embryo ([@bib29], [@bib33]). Within the AGM, intra-aortic hematopoietic clusters (IAHCs) containing HSCs appear to be associated with the major arteries at embryonic day (E)10.5--E11.5, including the vitelline and umbilical arteries ([@bib11], [@bib41]). There, specialized endothelial cells, termed hemogenic endothelium (HE) based on their localization and simultaneous expression of endothelial and hematopoietic markers, trans-differentiate into hematopoietic cells by an endothelial-to-hematopoietic transition (EHT) ([@bib1], [@bib2], [@bib22], [@bib40], [@bib48]). EHT has been shown to promote blood emergence not only in the embryo, but also in the extra-embryonic yolk sac (YS) ([@bib17]) and during *in vitro* differentiation of embryonic stem cells (ESCs) to blood ([@bib15], [@bib25], [@bib39]).

During ESC *in vitro* differentiation to blood, mesodermal hemangioblasts (HBs), defined as bipotential mesodermal progenitors with endothelial and hematopoietic potential, can be isolated based on FLK1 expression from embryoid bodies (EBs) and instructed to generate blood cells when cultured in hematopoiesis-promoting conditions ([@bib6], [@bib38]). During these cultures, VE-cadherin (CDH5)-positive endothelial cells emerge and aggregate as endothelial cores. Within these cores, CDH5^+^CD41^--^ HE cells, defined as HE1 ([@bib37], [@bib39]), further progress toward hematopoiesis by acquiring expression of the hematopoietic marker CD41. Spindle shaped CDH5^+^CD41^+^ HE cells, defined as HE2, then start to round up and bud as hematopoietic cells from the cores. This transition is correlated with concomitant loss of CDH5 expression and gain of CD45 expression by CDH5^−^CD41^+^ progenitors ([@bib15], [@bib26]).

The molecular mechanisms underlying the EHT process *in vivo* and *in vitro* remain poorly understood. One of the main drivers of HSC emergence is the transcription factor RUNX1, as its loss leads to a lack of definitive hematopoietic progenitors (HPs) due to a block in EHT ([@bib5], [@bib23], [@bib26], [@bib34], [@bib35]). Two of its downstream effectors are the transcriptional repressors GFI1 and GFI1B ([@bib24]). While loss of either *Gfi1* paralog has no apparent impact on EHT, *Gfi1/1b* double knockout (KO) HE cells cannot undergo EHT ([@bib42], [@bib43]). *Gfi1*s regulate EHT by recruiting the CoREST epigenetic remodeling complex in order to induce the silencing of the endothelial identity of the HE ([@bib42]). The CoREST complex contains the histone demethylase LSD1, CoREST, as well as both histone deacetylases, HDAC1 and HDAC2. Pharmacological inhibition or genetic deletion of LSD1 impairs the generation of blood cells ([@bib42]). These findings suggest that other chromatin-modifying enzymes than LSD1, such as HDACs, could have prominent roles in hematopoietic development. HDAC1 and HDAC2 can function alone or act in higher-order complexes such as the Sin3A, NuRD, and NODE multi-protein repressive complexes, in addition to the CoREST complex ([@bib21]). As part of these complexes, HDAC1 and HDAC2 proteins modulate gene expression by deacetylating the N-terminal tails of the core histones, resulting in the tightening of the chromatin, which reduces its accessibility for the transcriptional machinery.

The transforming growth factor β (TGF-β) pathway is critical for epithelial-to-mesenchymal transition (EMT) and was also shown recently to be involved in HE formation and EHT ([@bib31]). The pathway consists of a phosphorylation cascade; the TGF-β ligands (TGF-β1--4) bind to a type II receptor, which in turn recruits and phosphorylates a type I receptor. Subsequently, the type I receptor phosphorylates receptor-regulated SMADs (R-SMADS) which can now bind the common SMADs (Co-SMADs). R-SMAD/Co-SMAD complexes accumulate in the nucleus where they act as transcription factors to regulate gene expression ([@bib3]). The pathway also includes inhibitory SMADs (I-SMADs) that can block the R-Smad/Co-Smad dimerization. A similar signaling cascade is activated by bone morphogenetic protein (BMP) family receptors and leads to the phosphorylation of SMAD1/5 (pSMAD1/5), whereas active TGF-β/Activin A signaling leads to phosphorylation of SMAD2/3 (pSMAD2/3). The total level of pSMAD2/3 or pSMAD1/5 after stimulation with a ligand are further fine-tuned by a complex auto- and cross-regulations between R-SMADs and I-SMADs ([@bib27]).

In this study, we investigated the role of histone deacetylases during EHT first by pharmacologically inhibiting HDAC activity with the pan HDAC inhibitor trichostatin A (TSA). This treatment resulted in a significant impairment in hematopoietic cell generation from ESC-derived HE cells *in vitro* and from AGM HE cells *ex vivo*. We then focused on HDAC1 and HDAC2, which are prevalent members of the HDAC family and implicated in several epigenetic silencing complexes. Our results indicated that deletion of *Hdac1* or *Hdac2* individually resulted in a reduced generation of the CD41^+^ blood cells from HE. In contrast, the *Hdac1/2* double KO in HE cells led to intact specification toward the endothelial lineage, but cells initiating EHT underwent apoptosis during the process. To define the molecular changes occurring in *Hdac1* and *Hdac2* knockout HE cells, we performed global transcriptomic analysis on these cells, and determined the genome-wide DNA binding patterns of HDAC1 and HDAC2 in the same HE cell population. We found enrichment for members of the BMP and TGF-β signaling pathways among the genes deregulated in *Hdac1-* or *Hdac2*-deficient HE, and bound by the two histone modifiers. We validated the importance of TGF-β modulation by HDACs by partially rescuing the *Hdac1-* or *Hdac2*-deficient phenotype with treatment of the cultures with the TGF-β receptor inhibitor, SB431542 (SB43). Strikingly, addition of SB43 to *Hdac1* and/or *Hdac2* KO cultures did not decrease but increased the frequency of phosphorylated SMAD2/3. Finally, we observed that *ex vivo* treatment with SB43 increases EHT from wild-type AGM and YS HE cells. Altogether, these findings suggest that HDAC1 and HDAC2 activities are critical to modulate the TGF-β signaling pathway and the generation of blood cells through EHT, and that TGF-β activation in HE cells might therefore be beneficial for producing blood cells for regenerative therapies.

Results {#sec2}
=======

HDAC Inhibition Impairs EHT {#sec2.1}
---------------------------

Having previously shown the critical role of the histone demethylase LSD1 in EHT ([@bib42]), we wanted to explore the role of other epigenetic regulators in this process. HDAC proteins were obvious candidates given that they are members of multiple epigenetic silencing complexes. We first tested the impact of the inhibition of HDAC activity on blood formation *in vitro* using the pan-HDAC inhibitor TSA. For this, HBs were isolated from day 3 EBs based on the surface marker FLK1, and then cultured in blood formation-promoting culture conditions (Li-Blast). We treated wild-type cultures with TSA starting either from day 0 (FLK1 stage), day 1 or day 2 of Li-Blast culture, and analyzed the cultures at day 3 by fluorescence-activated cell sorting (FACS) ([Figures 1](#fig1){ref-type="fig"}A and 1B). TSA treatment before the onset of EHT, e.g., from FLK1 stage (day 0) or from day 1, dramatically affected the EHT process, which was monitored by the sequential acquisition of CD41 followed by the loss of CDH5 and the gain of CD45 expression. The frequencies of CD41^+^CDH5^--^ cells were severely decreased upon day 0 and day 1 TSA treatments but were not affected when the treatment was initiated from day 2 onward ([Figure 1](#fig1){ref-type="fig"}C). However, all the treated cultures presented a decreased frequency of CD45^+^ cells. These results indicated that inhibition of HDAC activity affects the generation of CD41^+^ cells, taking place mainly between day 0 and day 2, and the subsequent emergence of CD45^+^ cells. These initial findings suggested a potential requirement for HDAC activity in the EHT.Figure 1*In Vitro* Differentiation to Blood Is Reduced by HDAC Inhibition(A and B) Scheme of experimental setup. Flk1^*+*^ hemangioblasts were isolated from day 3 EBs and plated in Li-Blast cultures. Cultures were treated with 60 nM of TSA at day 0 (FLK1), day 1, or day 2, and (B) assessed by FACS for endothelial (CDH5) and hematopoietic (CD41 and CD45) markers. Blue squares indicate the quadrants depicted in (C). Representative FACS plots from three independent experiments.(C) Bar chart of averages of CD41^+^ (CDH5^--^) cells detected in three independent experiments.Error bars depict SEM. The p values were calculated with two-tailed Student\'s t test.

HDAC1 and HDAC2 were strong candidates for further studies as they are prominent members of the class I HDAC proteins (HDAC1, HDAC2, HDAC3, and HDAC8) that comprise enzymatically active HDACs ([@bib21]). In addition, our recent study of global gene expression of six sequential stages of hematopoietic specification and differentiation during *in vitro* differentiation to blood ([@bib18]) confirmed that *Hdac1* and *Hdac2* are indeed expressed in HBs, HEs, and HPs ([Figure S1](#mmc1){ref-type="supplementary-material"}A).

*Hdac1* and *Hdac2* Are Required for EHT {#sec2.2}
----------------------------------------

To circumvent the early developmental defects associated with the loss of HDAC1 or HDAC2 ([@bib32]), we employed a conditional KO (cKO) approach to genetically delete them only at the onset of EHT. For this, we made use of *Hdac1lox/lox, Hdac2lox/lox*, and *Hdac1lox/lox/Hdac2lox/lox* ESC lines that constitutively express CRE-ERT2 from the ROSA 26 locus ([@bib14], [@bib20]) allowing induction of CRE and genetic deletion of floxed genes by addition of tamoxifen (4-OHT). To first test the efficiency of *Hdac1* and *Hdac2* deletion, FLK1-positive cells were isolated from *Hdac1* or *Hdac2* cKO EBs and the deletion was induced by activation of the CRE-ERT2 at the FLK1 stage (day 0). Western blots performed on sorted HE cells (CDH5^+^CD41^+^) after 2 days of culture indicated a dramatic reduction in HDAC1 or HDAC2 protein levels in the tamoxifen-treated HEs (*Hdac1*Δ/Δ and Hdac2Δ/Δ; [Figure 2](#fig2){ref-type="fig"}A). Having validated the system, we focused on the role of HDAC1 and HDAC2 during EHT. Here, we induced the genetic deletions at the FLK1 stage (day 0) and performed FACS analyses at day 1, when the HE cells started to accumulate. FACS analysis and colony-forming assays (CFU-C) were also performed at day 3, when HPs are present ([Figure 2](#fig2){ref-type="fig"}B). We did not observe any significant differences in the frequencies of CD41^+^CDH5^--^ in *Hdac1*lox/lox or *Hdac1*Δ/Δ by flow cytometry by day 1. In contrast, by day 3, the frequencies of these cells, or the subsequent CD45^+^ cells generated upon successful EHT (acquisition of CD41 followed by loss of CDH5 and gain of CD45 positivity), were significantly lower in *Hdac1*Δ/Δ ([Figures 2](#fig2){ref-type="fig"}C, 2D, and [S1](#mmc1){ref-type="supplementary-material"}B). Consistent with an impaired EHT, we observed a marked decrease in the potential of these cells to give rise to different types of hematopoietic colonies ([Figure 2](#fig2){ref-type="fig"}E). Similar defects in EHT were observed upon deletion of *Hdac2* ([Figures 2](#fig2){ref-type="fig"}F--2H and [S1](#mmc1){ref-type="supplementary-material"}C), suggesting that both HDAC1 and HDAC2 are critical for EHT. In both instances, commitment to an endothelial and HE fate did not seem to be dramatically affected, as indicated by the presence of well-defined cell populations positive for the endothelial marker TIE-2 and the hematopoietic marker c-KIT ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). Actually the requirement for *Hdac1* and *Hdac2* in EHT might be under-evaluated by the time required to deplete the protein levels to a critical threshold, or by redundancy between the two proteins. Indeed, functional compensation between the highly related HDAC1 and HDAC2 has been observed in a number of cell types where deletion of both HDAC proteins led to more severe phenotypes than deletion of a single gene ([@bib13], [@bib32], [@bib46]). To evaluate if this functional redundancy between HDAC1 and HDAC2 took place during EHT, we repeated the experiments, using *Hdac1lox/lox/Hdac2lox/wt* and *Hdac1lox/lox/Hdac2lox/lox* cKO ESCs. Leaving one functional allele of *Hdac2* resulted in reduced frequencies of cells positive for CD41 and CD45 ([Figure S2](#mmc1){ref-type="supplementary-material"}), but mostly recapitulated the phenotype observed following *Hdac1* or *Hdac2* deletion. In contrast, simultaneous deletion of *Hdac1* and *Hdac2* (*Hdac1/2*Δ/Δ) resulted in a dramatic impairment in the generation of CD41^+^ and CD45^+^ hematopoietic cells ([Figures 3](#fig3){ref-type="fig"}A, 3B, and [S3](#mmc1){ref-type="supplementary-material"}A). Instead, CDH5-expressing endothelial cells and TIE-2^+^c-KIT^+^CD41^--^ HE1 cells accumulated in these cultures ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}B). Consistent with the severely reduced frequencies of CD41^+^ and CD45^+^ cells, *Hdac1/2* Δ/Δ cultures did not generate any viable hematopoietic colonies in CFU-C assays ([Figure 3](#fig3){ref-type="fig"}C) but only very small colonies consisting mostly of dying cells ([Figure S3](#mmc1){ref-type="supplementary-material"}C).Figure 2*Hdac1* or *Hdac2* Deletion Reduces Hematopoiesis(A) Western blot on HE (CDH5^+^/CD41^+^) cells derived from control and *Hdac1-* or *Hdac2*-deleted cultures. β-Actin was used as a loading control.(B) Scheme of the experimental setup. ESCs were differentiated to EBs before isolation of FLK1^*+*^ cells. Induction of *Hdac1* or *Hdac2* deletion was induced at this stage by addition of 4-hydroxy-tamoxifen (1 μM) in Li-Blast culture. Cultures were analyzed at days 1 and 3 by FACS. At day 3, a fraction of the cultures were also re-plated into CFU-C assays.(C) Representative FACS analysis at days 1 and 3 of *Hdac1lox/lox* and *Hdac1Δ/Δ* cultures. Cells were stained for the endothelial marker CDH5 and the hematopoietic marker CD41. The blue boxes indicate the CD41^+^ (CDH5^--^) gate used in the bar chart.(D) Bar chart quantifying the percentage of CD41 (CDH5^--^)- and CD45 (CDH5^--^)-positive cells generated at days 1 and 3 of Li-Blast from *Hdac1lox/lox* and *Hdac1Δ/Δ* cultures. Mean of three independent experiments (n = 3) are shown and p values were calculated with a paired t test.(E) CFU-C colony assay of day 3 *Hdac1lox/lox* and *Hdac1Δ/Δ* cultures. Mean of three independent experiments (n = 3) are shown with p values calculated with a paired t test.(F) Representative FACS analysis at days 1 and 3 of Li-Blast of *Hdac2lox/lox* and *Hdac2Δ/Δ* cultures. Staining for the endothelial marker CDH5 and for the hematopoietic marker CD41 is shown. The blue boxes indicate the CD41^+^ gate used in the bar chart.(G) Mean percentage from three independent experiments (n = 3) of the frequencies of CD41 (CDH5^--^)- and CD45 (CDH5^--^)-expressing cells at days 1 and 3 of *Hdac2lox/lox* and *Hdac2Δ/Δ* cultures are shown. The p values were calculated with a paired t test.(H) Day 3 *Hdac2lox/lox* and *Hdac2Δ/Δ* Li-Blast cultures were tested for CFU-C activity. Mean colony numbers from three independent experiments (n = 3).Error bars depict SEM. The p values were calculated with a paired t test.Figure 3*Hdac1/2* Double Deletion Abolishes Hematopoiesis(A) Representative FACS analysis of days 1 and 3 of *Hdac1/2lox/lox* and *Hdac1/2Δ/Δ* cultures. Cells were stained for the endothelial marker CDH5 and the hematopoietic marker CD41. The blue boxes indicate the CD41^+^CDH5^--^ gate used in the bar chart.(B) Bar graph quantification of the percentage of CD41^+^CDH5^--^- and CD45^+^CDH5^--^-positive cells detected in day 3 *Hdac1/2lox/lox* and *Hdac1/2Δ/Δ* cultures. Mean of three independent experiments (n = 3). The p values were calculated with a paired t test.(C) *Hdac1/2lox/lox* and *Hdac1/2Δ/Δ* day 3 cultures were subjected to CFU-C assay. Mean colony numbers from three independent experiments (n = 3) were shown. The p values were calculated with a paired t test.(D) Representative cell-cycle analysis with 5-ethynyl-2\'-deoxyuridine (EdU) on day 3 *Hdac1/2lox/lox* and *Hdac1/2Δ/Δ* cultures. No significant changes were observed between the samples.(E) Selected images extracted from time-lapse imaging (two independent experiments, n = 2) of *Hdac1/2lox/lox* and *Hdac1/2Δ/Δ* cultures. Cells with activated caspase-3/7 have a green fluorescent nuclear staining, indicative of apoptosis. Arrows depict hematopoietic progenitors.Error bars depict SEM.

Deletion or knockdown of HDAC protein levels have been previously linked to cell-cycle arrest and increased apoptosis ([@bib46]). To investigate if impairment in cell-cycle progression was the cause of the severe phenotype observed with the *Hdac1/2*Δ/Δ cells, we performed cell-cycle analysis on day 2 *Hdac1*Δ/Δ, *Hdac2*Δ/Δ, *Hdac1/2*Δ/Δ, and control cultures. The deleted cells displayed only a moderate increase in cells in G~1~/G~0~ and a limited decrease in the number of cells in the S phase of the cell cycle ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}D). Moreover, we did not detect any major difference in the cell-cycle status of the double *Hdac1/2*Δ/Δ cells compared with *Hdac1*Δ/Δ or *Hdac2*Δ/Δ single KO cells. In contrast, *Annexin V* staining for apoptotic cells at day 3 revealed a substantial increase in apoptosis, specifically in the CD41^+^ compartment of the *Hdac1/2*Δ/Δ cultures ([Figure S4](#mmc1){ref-type="supplementary-material"}). To further confirm and visualize the presence of apoptotic cells in the double KO, we performed time-lapse imaging on control and *Hdac1/2*Δ/Δ cell cultures in the presence of a reagent that is activated by caspase-3/7 to release a green DNA-binding fluorescent label marking the nuclei of apoptotic cells (IncuCyte Caspase-3/7 Green Apoptosis Assay Reagent). Control cells proliferated exponentially ([Figure S5](#mmc1){ref-type="supplementary-material"}A) and developed to round, floating hematopoietic cells ([Figure 3](#fig3){ref-type="fig"}E; [Video S1](#mmc3){ref-type="supplementary-material"}) in the presence of a constant level of Caspase-3/7-positive green cells ([Figure S5](#mmc1){ref-type="supplementary-material"}B; [Video S1](#mmc3){ref-type="supplementary-material"}). In contrast, in the *Hdac1/2*Δ/Δ cultures, the green label accumulated in adherent cells or in cells rounding up ([Video S2](#mmc4){ref-type="supplementary-material"}; [Figure 3](#fig3){ref-type="fig"}E). Altogether these results demonstrate a critical requirement for HDAC1 and HDAC2 in EHT. Loss of either HDAC1 or HDAC2 alone leads to reduced EHT, whereas the combined loss of HDAC1 and HDAC2 proteins results in apoptosis, notably in CD41^+^ cells, corresponding either to adherent HE2 cells or to the subsequent emerging round, hematopoietic cells. The absence of full compensatory redundancy in the single KO also suggests that HDAC1 and HDAC2 have distinct non-overlapping functions.

HDAC Activity Is Critical for *Ex Vivo* Production of Hematopoietic Cells from AGM HEs {#sec2.3}
--------------------------------------------------------------------------------------

We next wanted to evaluate the extent to which HDAC proteins are also required during *in vivo* EHT. We previously established that AGM CDH5^+^GFI1^+^c-KIT^--^ and CDH5^+^GFI1^+^c-KIT^+^ cells represent, respectively, HE cells and the subsequent cells starting to bud from the endothelial layer to form IAHCs ([@bib42]). To evaluate the requirement for HDAC activity in embryonic HE cells during EHT, we isolated these cells from E10.5 AGMs and cultured them on OP-9 stromal cells in the presence or absence of the HDAC inhibitor TSA ([Figure 4](#fig4){ref-type="fig"}A). After 7 days, CD41^+^ and CD45^+^ hematopoietic cells were readily detected in the control cultures initiated with either cell population ([Figures 4](#fig4){ref-type="fig"}B). In contrast, these hematopoietic cells were largely absent in TSA-treated cultures initiated with either CDH5^+^GFI1^+^c-KIT^--^ HE or CDH5^+^GFI1^+^c-KIT^+^ IAHC cells ([Figure 4](#fig4){ref-type="fig"}B). Consistent with these results, reduced numbers of HPs were generated from CDH5^+^GFI1^+^c-KIT^--^ HEs ([Figure 4](#fig4){ref-type="fig"}C), and almost no CFU-C were generated from TSA-treated cultures, even with the more advanced CDH5^+^GFI1^+^c-KIT^+^ IAHC cells, whereas control cells generated a large number of colonies ([Figures 4](#fig4){ref-type="fig"}C and 4D). Overall, these experiments demonstrate a critical role of HDAC activity in the *ex vivo* production of hematopoietic cells from AGM HEs.Figure 4Inhibition of HDAC Activity with TSA *Ex Vivo* Reduces Hematopoiesis(A) Scheme of the experimental procedure. In brief, E10.5 *Gfi1:tomato* AGMs were dissociated and sorted for HE (CDH5^+^Gfi1^+^c-KIT^--^) and IAHC (CDH5^+^Gfi1^+^c-KIT^+^). The cells were cultured on OP-9 for 7 days and were subjected to FACS and CFU-C assay.(B) Representative FACS of day 7 HE and IAHC cells cultures with or without 60 nM TSA. Cells were stained for the hematopoietic markers CD41 and CD45.(C) Hematopoietic output of HE cells calculated per one sorted HE cell from three independent experiments. The p values were calculated with a paired t test.(D) CFU-C assay performed in triplicates from cultures initiated with 40 cells of HE (n = 2) or IAHC (n = 1) treated or not with 60 nM TSA. Colonies were counted after 7--10 days.Error bars depict SEM. The p values were calculated with a paired t test.

HDAC1 and HDAC2 Bind to Endothelial Genes in HEs {#sec2.4}
------------------------------------------------

To identify the genes directly regulated by HDAC1 and HDAC2, we performed HDAC1 and HDAC2 chromatin immunoprecipitation sequencing (ChIP-seq) experiments on HE2 cells (CDH5^+^CD41^+^) from cultures initiated with FLK1^+^ cells. Analyses of the peaks indicated that HDAC1 binding was mostly found at promoter sites, whereas HDAC2 binding was more heterogeneous, and extended to intronic and intergenic regions ([Figures S6](#mmc1){ref-type="supplementary-material"}Ai and S6Bi). To obtain high-confidence target genes, we performed ChIP-seq with three different ESC lines (*Brachyury:GFP, Hdac1lox/lox*, and *Hdac2lox/lox*) ([Figures S6](#mmc1){ref-type="supplementary-material"}Aii and S6Bii). The resulting datasets were overlapped, and only targets bound in all three replicates were taken forward. These analyses identified 818 genes bound by both HDAC1 and HDAC2 and 1,326 and 998 genes associated with only HDAC1 or HDAC2 binding, respectively ([Figure 5](#fig5){ref-type="fig"}A). The gene ontology terms, enriched for the combined binding, showed relevance for cardiovascular system development and artery morphogenesis, supporting a role of HDAC proteins in regulating an endothelial program during EHT ([Figure 5](#fig5){ref-type="fig"}A; [Table S2](#mmc2){ref-type="supplementary-material"}), and possibly reflecting in part the role of HDAC proteins in the CoREST complex. We next performed whole genome RNA sequencing on control, *Hdac1ΔΔ*, or *Hdac2ΔΔ* cells ([Figure 5](#fig5){ref-type="fig"}B), and found 747 and 3,311 genes differentially expressed between control and *Hdac1ΔΔ* or *Hdac2ΔΔ* cells, respectively. The majority of these genes were upregulated, consistent with the role of HDAC proteins in transcriptional silencing complexes. In line with our *in vitro* observations, we observed downregulation of cell-cycle-related and upregulation of apoptosis-related genes ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B). We also observed deregulation of the expression of members of the TGF-β family ([Figure S7](#mmc1){ref-type="supplementary-material"}C). A total of 347 genes were upregulated upon either *Hdac1* or *Hdac2* deletion, with gene ontology analysis revealing their association with blood vessel, vascular, and cardiovascular system development ([Figure 5](#fig5){ref-type="fig"}C; [Table S2](#mmc2){ref-type="supplementary-material"}).Figure 5HDAC1 and HDAC2 Regulate Blood Vessel Development and TGF-β Signaling(A) Venn diagram of the intersection of genes bound by HDAC1 and HDAC2 in HE cells. Gene ontology analysis was performed on the 818 genes bound by HDAC1 and HDAC2. The p value (1.5 × 10^−263^) for the overlap probability of the gene lists was calculated with the hypergeometric method.(B) Heatmap showing the differentially expressed genes in the duplicate samples (n = 2) of *Hdac1lox/lox* versus *Hdac1Δ/Δ* and *Hdac2lox/lox* versus *Hdac2Δ/Δ*. Only genes deregulated more than 1.5-fold are presented.(C) Venn diagram intersecting the genes upregulated in *Hdac1Δ/Δ* and *Hdac2Δ/Δ*. Gene ontology analysis was performed on the 347 genes upregulated in both KOs. The p value (1.5 × 10^−224^) for the probability of the overlap of genes was calculated with the hypergeometric method.(D) Venn diagram combining deregulated genes in *Hdac1Δ/Δ* and/or *Hdac2Δ/Δ* and bound by HDAC1 and/or HDAC2. Forty-eight genes were present at the intersection of the four groups. Red, negative regulators of *Tgfβ*; green, positive regulator of *Tgfβ*.(E) Gene ontology analysis on the intersecting 48 genes.

TGF-β Signaling in HEs is Regulated by HDAC1 and HDAC2 {#sec2.5}
------------------------------------------------------

We then overlapped the binding data of HDAC1 and HDAC2 with the list of genes that are deregulated in *Hdac1Δ/Δ* or *Hdac2Δ/Δ* HE cells in order to identify candidates that are directly bound and regulated by the HDAC proteins. In total, we were left with 48 genes, which showed enrichment for transcriptional regulation, DNA binding, apoptosis, and MAD homology 1 Dwarfin type related to SMAD proteins ([Figures 5](#fig5){ref-type="fig"}D and 5E). Indeed, several members and regulators of the TGF-β pathways were present, including PTPN14, SMAD7, SMAD6, CRIM1, BMPER, and DACH1 and the expression of all these genes was upregulated in *Hdac*-deleted HEs ([Figures 5](#fig5){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}C; [Table S2](#mmc2){ref-type="supplementary-material"}). To validate our findings, we queried our recent survey from a previous study of global gene expression during six sequential stages of hematopoietic specification and differentiation ([@bib18]). Most of these members of TGF-β pathways were expressed at the HB and HE stage, and their expression decreased from the HE to the HP stage ([Figure 6](#fig6){ref-type="fig"}A). These results suggest that modulation of the TGF-β pathway through HDAC activity might be an important step in EHT.Figure 6SB43 Treatment Increases Hematopoiesis(A) RNA sequencing read counts (FPKM, reads per kilobase of transcript per million mapped reads) for the genes of interest in specified populations; MES, mesoderm; HB, hemangioblast; HE, hemogenic endothelium; and HP, hematopoietic progenitors.(B) *Hdac1lox/lox* and *Hdac2lox/lox* and *Hdac1/2lox/lox* treated with 4OHT or 4OHT + SB43. Day 3 cultures were stained for the endothelial marker CDH5 and the hematopoietic markers CD41. The black box indicates the CD41^+^CDH5^--^ gate used for the bar chart in (C).(C) Bar chart of averaged CD41^+^CDH5^--^ cells in DMSO control (*Hdac1* and/or *Hdac2* wild-type), 4OHT (*Hdac1* and/or *Hdac2* deletion), or 4OHT + SB43 (*Hdac1* and/or *Hdac2* deletion with SB43) from three independent experiments. The p values were determined with a paired t test.(D) Clonogenic assay (CFU-C) of DMSO ctrl (*Hdac1* and/or *Hdac2* wild-type), 4OHT (*Hdac1* and/or *Hdac2* deletion), or 4OHT + SB43 (*Hdac1* and/or *Hdac2* deletion with SB43) from three independent experiments. The p values were determined with a paired t test.(E) qPCR analysis of the six *Tgfβ*-related candidates on sorted HE cells. The expression levels of the indicated gene was normalized to β-actin and the value obtained in the Hdac1 and/or Hdac2 KO HE without SB43 set to a value 1. The value upon SB43 treatment was plotted relative to this level of 1 obtained without SB43. Averages from two independent experiments (n = 2).Error bars depict SEM.

TGF-β Activation Promotes EHT {#sec2.6}
-----------------------------

We next performed a series of experiments to test the influence of TGF-β signaling during *in vitro* differentiation of the *Hdac1* or *Hdac2* ESC lines, by adding either TGF-β1 to activate the TGF-β pathway or, alternatively treated *Hdac* KO cultures with SB431542 (SB43), a selective inhibitor of the receptor ALK5, and its relatives ALK4 and ALK7. Treating the cultures with TGF-β1 did not significantly alter the generation of CD41^+^ cells as observed by day 3 in cultures of *Hdac1*lox/lox*, Hdac2* lox/lox, *Hdac1*Δ/Δ, or *Hdac1/2*Δ/Δ (data not shown). In contrast, treatment with SB43 led to a restoration of normal frequencies of CD41^+^CDH5^--^ cells generated, as assessed by FACS in all the *Hdac* KO cultures ([Figures 6](#fig6){ref-type="fig"}B and 6C). Accordingly, time-lapse imaging of *Hdac1/2*Δ/Δ indicated that addition of SB43 rescued the budding of round cells, although these cells were not able to expand further ([Video S3. Hdac1/2 Double Knockout Cells Undergo Improved EHT with SB43, Related to Figure 6](#mmc5){ref-type="supplementary-material"}, [Video S4. Hdac1/2 Double Knockout Cells Undergo Improved EHT with SB43, Related to Figure 6](#mmc6){ref-type="supplementary-material"}, [Video S5. Hdac1/2 Double Knockout Cells Undergo Improved EHT with SB43, Related to Figure 6](#mmc7){ref-type="supplementary-material"}). Similarly, when the cells were assayed in the CFU-C assay, we observed a limited rescue of the blood colony-forming abilities only for the *Hdac1* KO ([Figure 6](#fig6){ref-type="fig"}D). These data suggest that modulation of TGF-β signaling is sufficient for partially rescuing the impaired EHT in the absence of HDAC1 and/or HDAC2, but not for restoring further proliferation and survival. Finally, qPCR analysis on isolated HEs of the *Hdac1*, *Hdac2*, and *Hdac1/2* KO HEs treated with SB43 indicated significant reduction in the gene expression level of the TGF-β members that were upregulated in the *Hdac* KO cultures ([Figure 6](#fig6){ref-type="fig"}E), consistent with the hypothesis that the observed EHT defects in *Hdac1*, *Hdac2*, and *Hdac1/2* KO cultures were indeed caused by a deregulation of TGF-β. To further confirm these findings, we determined the overall pSMAD2/3 levels in *Hdac1*, *Hdac2*, and *Hdac1/2* KO HE with and without SB43 treatment, as a readout for TGF-β signaling. We performed imaging using flow cytometry for the HE markers CDH5 and CD41 combined with intracellular detection of pSMAD2/3 and DAPI. In line with the elevated levels of negative regulators of TGF-β (SMAD7, SMAD6, CRIM1, BMPER, and DACH1) in *Hdac1*, *Hdac2*, and *Hdac1/2* KO HEs, we observed significant reduction of total pSMAD2/3 in the *Hdac* KO HEs compared with the non-deleted counterpart ([Figures 7](#fig7){ref-type="fig"}A and 7B). More surprisingly, pSMAD2/3 levels in the *Hdac1*, *Hdac2*, and *Hdac1/2* HEs was restored to wild-type levels upon SB43 treatment ([Figures 7](#fig7){ref-type="fig"}A and 7B), thereby indicating that the rescued EHT is associated with restoration of TGF-β signaling. To further validate our findings in the context of *in vivo* EHT, we performed immunohistochemistry for pSMAD2/3 in combination with staining for the endothelial marker CD31, and the IAHC marker CD41, on E10.5 AGM sections. We detected pSMAD2/3 accumulation in budding cells and hematopoietic clusters of the AGM ([Figures 7](#fig7){ref-type="fig"}C and [S8](#mmc1){ref-type="supplementary-material"}), further correlating a successful EHT with activation of TGF-β signaling. Finally, we examined if modulation of TGF-β signaling could also be implicated in EHT by AGM or YS HE cells. For this, we sorted individual single CDH5^+^GFI1^+^c-KIT^--^ HE cells into single wells in the presence of OP-9 stromal cells ([Figure 7](#fig7){ref-type="fig"}D). The cultures were treated with either DMSO (control) or SB43. Assessment of the hematopoietic potential after 7 days of culture revealed a significant increase in the frequency of blood colonies in SB43-treated cultures. We also observed significantly larger colonies in these cultures compared with control-treated cultures ([Figure 7](#fig7){ref-type="fig"}E). Therefore SB43 treatment not only increases EHT frequency, but also has a proliferative effect on the emerging progenitors. Altogether these experiments indicate that TGF-β activation promotes EHT, and that the defective EHT observed in Hdac1Δ/Δ, Hdac2Δ/Δ, and Hdac1/2Δ/Δ, cultures could be, to some extent, rescued by activation of TGF-β signaling.Figure 7SB43 Treatment Increases TGF-β Signaling in *Hdac1* and/or *Hdac2* KO HE(A) Representative pSMAD2/3 levels in *Hdac1lox/lox*, *Hdac1Δ/Δ*, and *Hdac1Δ/Δ*+SB43 from ImageStream analysis.(B) Averaged pSMAD2/3 levels from three independent experiments of the indicated cultures. The p values were calculated with a paired t test.(C) Immunohistochemistry for the endothelial marker CD31, IAHC marker CD41, and pSMAD2/3 levels on E10.5 AGM section. Arrows depicts IAHC. Scale bar, 10 μm.(D) Hematopoietic colony assay on single cells. E10.5 *Gfi1:tomato* AGMs were dissociated and sorted for HE (CDH5^+^Gfi1^+^c-KIT^--^) and cultured on OP-9 for 7 days.(E) Single HE cells (CDH5^+^Gfi1^+^c-KIT^--^) from E10.5 AGM (n = 4) were sorted into individual wells with or without SB43. Colonies were scored and images were taken 7 days later. Scale bar, 100 μm.Error bars depict SEM.

Discussion {#sec3}
==========

The molecular and cellular regulation of blood cell formation through EHT remains poorly understood. We previously determined that the CoREST epigenetic silencing complex, and in particular the histone demethylase LSD1, is implicated in the downregulation of the endothelial program during the transition from endothelial to hematopoietic cells ([@bib42]). However, the potential functions of the other chromatin-modifying proteins, such as HDACs, in the EHT process are just starting to be explored. Indeed, several HDACs were shown to be implicated in the generation of definitive blood formation, notably through reverse genetic screens in zebrafish ([@bib4], [@bib19]), but the exact stages of blood cell development affected remain poorly characterized. In one of these studies, *Hdac1* was shown to be required for *Runx1* expression downstream of *Notch* signaling*,* suggesting an early role before EHT. In a follow-up study, HDAC1, HDAC2, and HDAC9a were proposed to function, notably through an HDAC-NuRD deacetylase complex, in the specification or maintenance of hematopoietic cells from the HEs. This would therefore be compatible with a role of these HDACs in EHT.

In this study, we pharmacologically inhibited HDAC activity with the pan-HDAC inhibitor TSA and observed a significant impairment in the generation of hematopoietic cells from ESC-derived HE cells *in vitro* and from AGM HE cells *ex vivo*. We then focused on HDAC1 and HDAC2, which are implicated in several epigenetic silencing complexes, and therefore could be implicated in the EHT as part of one or several of these complexes. Accordingly, we demonstrated a significantly reduced EHT upon HDAC1 and/or HDAC2 deletion. Consistent with functional redundancy and compensation between HDAC1 and HDAC2, we found a much more severe block in EHT in the absence of both proteins. Loss of both HDAC proteins led to a dramatic increase in apoptosis, specifically in CD41^+^ cells that are undergoing EHT. Interestingly, the deletion of Sin3a has also been shown to be associated with increased apoptosis ([@bib8], [@bib10]), suggesting that the role of HDAC1 and HDAC2 identified here could reflect their function as part of the Sin3a repressive complex. We also found that HDAC1 and/or HDAC2 genetic deletions and binding was associated with genes implicated in cardiovascular system development. These findings would be compatible with roles of HDAC1 and HDAC2 in the CoREST repressive complex previously shown to be critical for the downregulation of the endothelial program during EHT.

In addition, our results suggested that HDAC1 and HDAC2 regulate hematopoietic emergence through the modulation of the TGF-β signaling pathway. Accordingly, we experimentally demonstrated both *in vitro* and *in vivo* that modulation of this pathway in HE cells reinforces hematopoietic development and that activation of TGF-β signaling is associated with a successful EHT. TGF-β is strongly associated with EMT that, like EHT, requires loss of cell-cell contact and change in morphology. EMT and its reverse process, mesenchymal-to-epithelial transition, are naturally occurring processes during development that are hijacked in cancers ([@bib44]). The main hallmarks of EMT are induction of the TGF-β downstream effectors *snail/slug* and *zeb1/2* genes ([@bib44]). The implication of TGF-β in the EHT is further supported by recent RNA sequencing of AGM populations, including HE and IAHC, which revealed *snail* and *zeb* expression during the EC to pre-HSC transition ([@bib47]) and their specific accumulation in the hematopoietic competent part of the dorsal aorta ([@bib28]). Similarly, in agreement with an essential positive requirement for TGF-β in the EHT, knockdown of the receptor TGF-βRII, or the ligands TGF-β1 or TGF-β, were shown to impair HE specification ([@bib31]). In contrast, a recent study suggested that activation of TGF-β signaling impairs EHT ([@bib45]). However, this was mostly based on results obtained with SB43, which was considered as a negative regulator of the pathway, whereas in our hands SB43 surprisingly leads to increased pSMAD2/3 signaling. Our observations were confirmed by recent findings showing that SB43 only has a negative impact on pSMAD2/3 levels for a very short time. After this initial phase of repression, SB43 induces an increase in pSMAD2/3 levels by an unknown mechanism ([@bib36]). Interestingly, these authors argue for a role of pSMAD2/3 in cell fate switching, and acceleration of this switch, which would be compatible with our findings. Indeed, we detected an increase in E10.5 AGM HEs undergoing EHT following SB43 addition, suggesting that the HE population has more EHT competent precursors than detected in the wild-type setting. Overall, TGF-β signaling in HE cells could therefore participate in their cell fate conversion to hematopoietic cells.

In conclusion, we have established here that HDAC1 and HDAC2 are individually required but not essential for hematopoietic emergence. In contrast, deletion of both genes results in apoptosis of CD41^+^ cells undergoing EHT and a complete lack of functional HP generation. We also demonstrated that HDAC1 and HDAC2 regulate EHT at least in part through the modulation of the TGF-β signaling pathway. These results suggest that modulation of HDAC activity and TGF-β activation in HE cells might be beneficial for producing blood cells through *in vitro* differentiation or reprogramming.

Experimental Procedures {#sec4}
=======================

ESC Line Growth and Differentiation {#sec4.1}
-----------------------------------

*Bry-GFP* ([@bib16]), *Hdac1lox/lox*, *Hdac2*l*ox/lox Hdac1lox/loxHdawt/lox*, and *Hdac1/2lox/lox* ESC lines ([@bib14]) were used. ESC cultures, maintenance, and differentiation and composition of the different media were described previously ([@bib37], [@bib38]). For SB431542 treatment, 10 μM of the compound was added to the Li-Blast culture at FLK1 stage.

Time-Lapse Imaging of Li-Blast Cultures and Caspase-3/7 Staining Assay {#sec4.2}
----------------------------------------------------------------------

*Hdac1/2*lox/lox ESC lines were cultured and differentiated as described above. For time-lapse imaging, day 3 FLK1^+^ cells were replated at 6.5 × 10^4^ cells per well in six-well plates and time-lapse imaging was initiated the following day using an IncuCyte Zoom device (Essen Instruments). For caspase-3/7 staining assay, a 1:200 dilution of the caspase-3/7 GFP reagent was added to stain apoptotic cells (IncuCyte Caspase-3/7 Green Apoptosis Assay Reagent, cat. no. 4440). The movies were processed and labeled with Final Cut Pro X (Apple).

CFU-C Assays {#sec4.3}
------------

CFU-C assays were performed as described previously ([@bib37]).

Mouse Lines and Animal Work {#sec4.4}
---------------------------

The *Gfi1:tomato* mouse line have been described previously ([@bib42]). For time matings, wild-type ICR females (aged 6--12 weeks) were mated to *Gfi1*^*tomat*^ males (C57/Bl6, aged 6--20 weeks). These embryos were genotyped and used for AGM/YS HE or IAHC sorts. Vaginal plug detection was considered as day 0.5. All animal work was performed under regulation in accordance with the United Kingdom Animal Scientific Procedures Act (ASPA) 1986 and was approved by the Animal Welfare and Ethics Review Body (AWERB) of the Cancer Research UK Manchester Institute.

*In Vitro* Culture of AGM Cells on OP-9 Stromal Cells {#sec4.5}
-----------------------------------------------------

*In vitro* culture of AGM cells was performed as described previously ([@bib42]).

EdU and Annexin V Staining {#sec4.6}
--------------------------

5-Ethynyl-2\'-deoxyuridine (EdU) and Annexin V/7AAD staining were performed on days 2 and 3 of blast cultures according to the manufacturer\'s instructions (Click-iT EdU Alexa 647, Invitrogen, cat. no. C10419 and AnnexinV Apoptosis Detection Kit from eBioscience, cat. no. 88-8007-72) and analyzed on an LSRII (BD Biosciences).

pSMAD2/3 Stain for ImageStream Analysis {#sec4.7}
---------------------------------------

Day 2 Li-Blast cells were fixed for 15 min at room temperature in 4% paraformaldehyde and subsequently permeabilized in 90% methanol overnight at −20°C. Cells were stained according to the manufacturer\'s instructions. The samples were washed and run on Amnis Imaging Flow Cytometer X. Data were analyzed with IDEAS software.

Flow Cytometry and Cell Sorting {#sec4.8}
-------------------------------

Stained cells were analyzed on a Fortessa (BD Biosciences). Sorts were performed on FACSAria III, BD Influx (BD Biosciences), or by magnetic sorting (Miltenyi Biotec). The antibodies and streptavidin used were FLK-1-bio, TIE2-PE, c-KIT-APC-eFluor780, CD41-PE, CDH5--APC, CD41-PE-Cy7, or CD45-PerCPCy5.5. A detailed list of antibodies and the dilutions used is provided in [Table S1](#mmc8){ref-type="supplementary-material"}. FACS data were analyzed using the FlowJo software (TreeStar).

Immunohistochemistry {#sec4.9}
--------------------

AGM sections were stained as described previously ([@bib42]) and mounted using Prolong Gold Antifade medium with DAPI (Life Technologies). Images were taken using a low-light time-lapse microscope (Leica) using the Metamorph imaging software, and images were processed using ImageJ.

ChIP {#sec4.10}
----

ChIP experiments for HDAC1 and HDAC2 were performed with 0.5 × 10^6^ HE2 (CDH5^+^/CD41^+^) cells per ChIP according to the manufacturer\'s instructions (HighCell Kit, Diagenode, cat. no. C01010060). Sequencing libraries were prepared with the Diagenode MicroPlex Library Preparation Kit v.2 (Diagenode, cat. no. C05010012). The ChIP samples were sequenced on an Illumina HiSeq 2500.

RNA Extraction and Whole-Genome RNA Sequencing {#sec4.11}
----------------------------------------------

HE cells (CDH5^+^/CD41^+^) were isolated from day 2 cultures of *Hdac1*lox/lox, *Hdac2* lox/lox*, Hdac1*Δ/Δ, and *Hdac2*Δ/Δ. RNA was extracted using the QIAGEN RNAeasy Micro Kit. One nanogram of RNA was processed with SureSelect Strand-Specific RNA Library Prep for Illumina (cat. code: G9691A, Agilent) according to the manufacturer\'s instructions and run on an Illumina HiSeq as a single ends (1 × 75 bp) run.

RNA Sequencing Data Analysis {#sec4.12}
----------------------------

Basecall files generated from a HiSeq sequencing run were converted to FASTQ format with Illumina\'s bcl2fastq (v.2.17.1.14). Lane-wise alignment was performed by bowtie2 (v.2.2.1) to mouse reference genome mm10 with default parameters. Generated SAM files from bowtie2 alignment were converted to BAM files by samtools v.0.1.19. Parameters for samtools SAM to BAM conversion: -q 10 -f 2 -F 268. Resulting lane-wise BAM files from the same sequence library were merged into one BAM file used for downstream analysis. Read counts from BAM files were extracted under the R environment (R v.3.1.0) with the package Rsubread v.1.13.13. Only genes with at least one count per million in all samples were retained for differential expression analysis. The count table was loaded to edgeR v.3.8.5 and differentially expressed genes between groups were identified by exact test function.

ChIP-Seq Data Analysis {#sec4.13}
----------------------

Basecall files generated from HiSeq sequencing run were converted to FASTQ format with Illumina\'s bcl2fastq. Alignment was performed by bowtie2 (v.2.2.1) to mouse reference genome mm10 with default parameters. Generated SAM files from bowtie2 alignment were converted to BAM files by samtools v.0.1.19. Parameters for samtools SAM to BAM conversion: -bS -q 10 -F 260. Peaks were called using the program macs2 (v. 2.1.0.20150420) with the settings -q 0.01. Full pipeline repo available at: <https://github.com/mproffitt/BioWorkflow>.
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